A detailed history of Driehaus Capital Management LLC transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Driehaus Capital Management LLC holds 1,400,191 shares of OVID stock, worth $1.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,400,191
Previous 1,400,191 -0.0%
Holding current value
$1.4 Million
Previous $1.08 Million 53.25%
% of portfolio
0.02%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.7 - $3.34 $980,133 - $4.68 Million
1,400,191 New
1,400,191 $1.08 Million
Q1 2023

May 15, 2023

SELL
$1.88 - $2.85 $325,110 - $492,853
-172,931 Reduced 12.09%
1,257,337 $3.24 Million
Q3 2022

Nov 14, 2022

BUY
$1.84 - $2.26 $159,975 - $196,491
86,943 Added 6.47%
1,430,268 $2.63 Million
Q2 2022

Aug 15, 2022

BUY
$1.69 - $3.31 $1.66 Million - $3.25 Million
983,349 Added 273.17%
1,343,325 $2.89 Million
Q1 2022

May 16, 2022

BUY
$2.65 - $3.49 $953,936 - $1.26 Million
359,976 New
359,976 $1.13 Million
Q4 2018

Feb 14, 2019

SELL
$2.42 - $6.6 $510,878 - $1.39 Million
-211,107 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$5.6 - $11.0 $415,475 - $816,112
-74,192 Reduced 26.0%
211,107 $1.2 Million
Q2 2018

Aug 14, 2018

BUY
$6.16 - $10.14 $8,506 - $14,003
1,381 Added 0.49%
285,299 $2.23 Million
Q1 2018

May 15, 2018

BUY
$6.53 - $9.82 $79,803 - $120,010
12,221 Added 4.5%
283,918 $2.01 Million
Q4 2017

Feb 14, 2018

BUY
$6.12 - $12.31 $41,616 - $83,708
6,800 Added 2.57%
271,697 $2.68 Million
Q3 2017

Nov 14, 2017

BUY
$5.32 - $9.77 $1.41 Million - $2.59 Million
264,897
264,897 $2.27 Million

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $70.4M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.